Single-dose versus five-day treatment with trimethoprim for the acute dysuria/pyuria syndrome in women.

Abstract

The efficacy of a single dose trimethoprim in the treatment of the dysuria/pyuria syndrome in women was prospectively studied in an open, controlled and randomized trail. Of 90 women aged 18-60 years 68 had and 22 had not significant bacteriuria when the urine was cultured. The 42 women in the single-dose group received trimethoprim 400 mg once while the 48 in the multi-dose group received trimethoprim 200 mg X 2 for five days. One week after ended treatment 83% were cured in the single-dose group, and 85% in the multi-dose group. One relapse and six reinfections occurred in the single-dose group, no relapse and seven reinfections in the multi-dose group. Two patients in the single-dose group and eight in the multi-dose group reported adverse effects. A single dose of trimethoprim seems to be safe and effective in the treatment of acute dysuria/pyuria syndrome in women.

• Authors: A Baerheim
• Journal: Scandinavian journal of primary health care (Scand J Prim Health Care) Vol. 5 Issue 2 Pg. 87-90 (May 1987) ISSN: 0281-3432 [Print] United States
• PMID: 3616278 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Trimethoprim

Topics

• Acute Disease
• Adolescent
• Adult
• Female
• Humans
• Middle Aged
• Pyuria (drug therapy)
• Random Allocation
• Recurrence
• Trimethoprim (administration & dosage, adverse effects)
• Urinary Tract Infections (drug therapy)